Brilinta vs Vascepa
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Brilinta | US Vascepa | |
|---|---|---|
| Generic name | ticagrelor | icosapent ethyl |
| Drug class | P2Y12 Platelet Inhibitor (Antiplatelet) | Omega-3 Fatty Acid (EPA) |
| Treats | Acute coronary syndrome, heart attack prevention | High triglycerides, cardiovascular risk reduction |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | AstraZeneca | Amarin |
| Year approved | 2011 | 2012 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $120M | $90M |
| Common side effects | Bleeding, Shortness of breath, Bruising, Headache | Atrial fibrillation, Bleeding risk, Joint pain, Swelling |
Frequently asked questions
Is Brilinta or Vascepa better?
Neither is universally "better." Brilinta (ticagrelor) and Vascepa (icosapent ethyl) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Brilinta and Vascepa?
Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca, while Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Brilinta has the larger estimated TV advertising budget of the two.